Cargando…

Monocarboxylate Transporter 1 (MCT1) in Liver Pathology

Membrane monocarboxylate transporter 1 (SLC16A1/MCT1) plays an important role in hepatocyte homeostasis, as well as drug handling. However, there is no available information about the impact of liver pathology on the transporter levels and function. The study was aimed to quantify SLC16A1 mRNA (qRT-...

Descripción completa

Detalles Bibliográficos
Autores principales: Droździk, Marek, Szeląg-Pieniek, Sylwia, Grzegółkowska, Justyna, Łapczuk-Romańska, Joanna, Post, Mariola, Domagała, Pawel, Miętkiewski, Janusz, Oswald, Stefan, Kurzawski, Mateusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084425/
https://www.ncbi.nlm.nih.gov/pubmed/32111097
http://dx.doi.org/10.3390/ijms21051606
_version_ 1783508718745288704
author Droździk, Marek
Szeląg-Pieniek, Sylwia
Grzegółkowska, Justyna
Łapczuk-Romańska, Joanna
Post, Mariola
Domagała, Pawel
Miętkiewski, Janusz
Oswald, Stefan
Kurzawski, Mateusz
author_facet Droździk, Marek
Szeląg-Pieniek, Sylwia
Grzegółkowska, Justyna
Łapczuk-Romańska, Joanna
Post, Mariola
Domagała, Pawel
Miętkiewski, Janusz
Oswald, Stefan
Kurzawski, Mateusz
author_sort Droździk, Marek
collection PubMed
description Membrane monocarboxylate transporter 1 (SLC16A1/MCT1) plays an important role in hepatocyte homeostasis, as well as drug handling. However, there is no available information about the impact of liver pathology on the transporter levels and function. The study was aimed to quantify SLC16A1 mRNA (qRT-PCR) and MCT1 protein abundance (liquid chromatography–tandem mass spectrometry (LC¬¬–MS/MS)) in the livers of patients diagnosed, according to the standard clinical criteria, with hepatitis C, primary biliary cirrhosis, primary sclerosing hepatitis, alcoholic liver disease (ALD), and autoimmune hepatitis. The stage of liver dysfunction was classified according to Child–Pugh score. Downregulation of SLC16A1/MCT1 levels was observed in all liver pathology states, significantly for ALD. The progression of liver dysfunction, from Child–Pugh class A to C, involved the gradual decline in SLC16A1 mRNA and MCT1 protein abundance, reaching a clinically significant decrease in class C livers. Reduced levels of MCT1 were associated with significant intracellular lactate accumulation. The MCT1 transcript and protein did not demonstrate significant correlations regardless of the liver pathology analyzed, as well as the disease stage, suggesting posttranscriptional regulation, and several microRNAs were found as potential regulators of MCT1 abundance. MCT1 membrane immunolocalization without cytoplasmic retention was observed in all studied liver pathologies. Overall, the study demonstrates that SLC16A1/MCT1 is involved in liver pathology, especially in ALD.
format Online
Article
Text
id pubmed-7084425
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70844252020-03-24 Monocarboxylate Transporter 1 (MCT1) in Liver Pathology Droździk, Marek Szeląg-Pieniek, Sylwia Grzegółkowska, Justyna Łapczuk-Romańska, Joanna Post, Mariola Domagała, Pawel Miętkiewski, Janusz Oswald, Stefan Kurzawski, Mateusz Int J Mol Sci Article Membrane monocarboxylate transporter 1 (SLC16A1/MCT1) plays an important role in hepatocyte homeostasis, as well as drug handling. However, there is no available information about the impact of liver pathology on the transporter levels and function. The study was aimed to quantify SLC16A1 mRNA (qRT-PCR) and MCT1 protein abundance (liquid chromatography–tandem mass spectrometry (LC¬¬–MS/MS)) in the livers of patients diagnosed, according to the standard clinical criteria, with hepatitis C, primary biliary cirrhosis, primary sclerosing hepatitis, alcoholic liver disease (ALD), and autoimmune hepatitis. The stage of liver dysfunction was classified according to Child–Pugh score. Downregulation of SLC16A1/MCT1 levels was observed in all liver pathology states, significantly for ALD. The progression of liver dysfunction, from Child–Pugh class A to C, involved the gradual decline in SLC16A1 mRNA and MCT1 protein abundance, reaching a clinically significant decrease in class C livers. Reduced levels of MCT1 were associated with significant intracellular lactate accumulation. The MCT1 transcript and protein did not demonstrate significant correlations regardless of the liver pathology analyzed, as well as the disease stage, suggesting posttranscriptional regulation, and several microRNAs were found as potential regulators of MCT1 abundance. MCT1 membrane immunolocalization without cytoplasmic retention was observed in all studied liver pathologies. Overall, the study demonstrates that SLC16A1/MCT1 is involved in liver pathology, especially in ALD. MDPI 2020-02-26 /pmc/articles/PMC7084425/ /pubmed/32111097 http://dx.doi.org/10.3390/ijms21051606 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Droździk, Marek
Szeląg-Pieniek, Sylwia
Grzegółkowska, Justyna
Łapczuk-Romańska, Joanna
Post, Mariola
Domagała, Pawel
Miętkiewski, Janusz
Oswald, Stefan
Kurzawski, Mateusz
Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
title Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
title_full Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
title_fullStr Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
title_full_unstemmed Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
title_short Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
title_sort monocarboxylate transporter 1 (mct1) in liver pathology
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084425/
https://www.ncbi.nlm.nih.gov/pubmed/32111097
http://dx.doi.org/10.3390/ijms21051606
work_keys_str_mv AT drozdzikmarek monocarboxylatetransporter1mct1inliverpathology
AT szelagpienieksylwia monocarboxylatetransporter1mct1inliverpathology
AT grzegołkowskajustyna monocarboxylatetransporter1mct1inliverpathology
AT łapczukromanskajoanna monocarboxylatetransporter1mct1inliverpathology
AT postmariola monocarboxylatetransporter1mct1inliverpathology
AT domagałapawel monocarboxylatetransporter1mct1inliverpathology
AT mietkiewskijanusz monocarboxylatetransporter1mct1inliverpathology
AT oswaldstefan monocarboxylatetransporter1mct1inliverpathology
AT kurzawskimateusz monocarboxylatetransporter1mct1inliverpathology